PMID- 30209442
OWN - NLM
STAT- MEDLINE
DCOM- 20181126
LR  - 20181126
IS  - 1699-3993 (Print)
IS  - 1699-3993 (Linking)
VI  - 54
IP  - 8
DP  - 2018 Aug
TI  - Targeted agents in the management of small cell lung cancer - present and future.
PG  - 479-488
LID - 10.1358/dot.2018.54.8.2833977 [doi]
AB  - Lung cancer is the leading cause of cancer-related mortality worldwide and is the 
      second most common cancer in both sexes. The small cell lung cancer (SCLC) 
      subtype constitutes about 13% to 15% of all diagnosed lung cancers with an 
      expected 5-year mortality of about 90%. In the past decades, various strategies 
      used to treat newly diagnosed, relapsed or refractory SCLC have shown no 
      significant improvement in clinical outcomes. In the genomic era of oncology, 
      with a better understanding of tumor biology and pathway specific investigations, 
      multiple investigational agents have been studied with the aim to improve 
      clinical outcomes. Some of them include epidermal growth factor receptor tyrosine 
      kinase inhibitors (EGFR-TKIs), BCR-ABL TKIs, mammalian target of rapamycin (mTOR) 
      inhibitors, vascular endothelial growth factor (VEGF) inhibitors, etc. All of 
      them have been unsuccessful in adding any survival advantage. DNA repair 
      inhibitors, immunotherapies and anti-delta-like protein 3 (DLL3) antibody-drug 
      conjugates have also been tested so far. This article aims to review the current 
      literature and investigational approaches to improving clinical outcomes of SCLC.
CI  - Copyright 2018 Clarivate Analytics.
FAU - Srivastava, Roma
AU  - Srivastava R
AD  - Department of Hematology/Medical Oncology, Joan C. Edwards School of Medicine, 
      Marshall University, Huntington, West Virginia, USA. romaonco@gmail.com.
FAU - Lebowicz, Y
AU  - Lebowicz Y
AD  - Department of Hematology/Medical Oncology, Joan C. Edwards School of Medicine, 
      Marshall University, Huntington, West Virginia, USA.
FAU - Jamil, M O
AU  - Jamil MO
AD  - Department of Hematology/Medical Oncology, Joan C. Edwards School of Medicine, 
      Marshall University, Huntington, West Virginia, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Spain
TA  - Drugs Today (Barc)
JT  - Drugs of today (Barcelona, Spain : 1998)
JID - 101160518
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Radiopharmaceuticals)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Antineoplastic Agents, Immunological/therapeutic use
MH  - Apoptosis/drug effects
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/metabolism/pathology
MH  - Cell Proliferation/drug effects
MH  - Clinical Decision-Making
MH  - DNA Repair/drug effects
MH  - Genetic Therapy
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/genetics/metabolism/pathology
MH  - Molecular Targeted Therapy/adverse effects/*methods
MH  - Neoplastic Stem Cells/drug effects/metabolism/pathology
MH  - Precision Medicine/adverse effects/*methods
MH  - Radiopharmaceuticals/therapeutic use
MH  - Signal Transduction/drug effects
OTO - NOTNLM
OT  - Cancer immunotherapy
OT  - Novel cancer agents
OT  - Small cell lung cancer
OT  - Targeted cancer therapies
EDAT- 2018/09/14 06:00
MHDA- 2018/11/27 06:00
CRDT- 2018/09/14 06:00
PHST- 2018/09/14 06:00 [entrez]
PHST- 2018/09/14 06:00 [pubmed]
PHST- 2018/11/27 06:00 [medline]
AID - 2833977 [pii]
AID - 10.1358/dot.2018.54.8.2833977 [doi]
PST - ppublish
SO  - Drugs Today (Barc). 2018 Aug;54(8):479-488. doi: 10.1358/dot.2018.54.8.2833977.